NO20063020L - Protein NMB1125 og anvendelse derav i farmasoytiske formuleringer - Google Patents
Protein NMB1125 og anvendelse derav i farmasoytiske formuleringerInfo
- Publication number
- NO20063020L NO20063020L NO20063020A NO20063020A NO20063020L NO 20063020 L NO20063020 L NO 20063020L NO 20063020 A NO20063020 A NO 20063020A NO 20063020 A NO20063020 A NO 20063020A NO 20063020 L NO20063020 L NO 20063020L
- Authority
- NO
- Norway
- Prior art keywords
- formulations
- origin
- ability
- diseases
- nmb1125
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 241000588650 Neisseria meningitidis Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Anvendelse av et nytt vaksineantigen anvendt som forebyggende eller terapeutisk redskap mot sykdommer generelt, hvor slike sykdommer kan ha bakterielt opphav, viralt opphav, være kreftrelatert eller ha annet opphav. Det tekniske formål som ligger til grunn for foreliggende oppfinnelse, er utviklingen av formuleringer med evnen til å øke beskyttelsesspektret av eksisterende vaksiner og dermed ekspandere dem mot forskjellige patogener. For å oppnå dette mål, ble NMB1125-protein isolert og identifisert som komponent av ytre membranpreparater av Neisseria meningitidis som har evnen til å indusere baktericidal aktivitet. I tillegg ble genet som koder for NMB1125-protein, klonet og uttrykt, og polypeptidet ble renset og dets immunogenisitet ble bedømt i dyremodeller. Sekvensdataen fra homologe gener viste, grunnet den høye grad av konservering, dets store verdi som målantigen av en kryssreaktiv respons når det presenteres via forskjellige ruter. Resulterende formuleringer ifølge oppfinnelsen er nyttige innen den farmasøytiske industri som vaksineformuleringer for humant bruk.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20030285A CU23237A1 (es) | 2003-12-03 | 2003-12-03 | PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS |
| PCT/CU2004/000015 WO2005054281A2 (es) | 2003-12-03 | 2004-12-02 | Proteína nmb1125 y su uso en formulaciones farmaceuticas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20063020L true NO20063020L (no) | 2006-09-01 |
Family
ID=40091628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20063020A NO20063020L (no) | 2003-12-03 | 2006-06-28 | Protein NMB1125 og anvendelse derav i farmasoytiske formuleringer |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7691971B2 (no) |
| EP (1) | EP1693378B9 (no) |
| KR (1) | KR20060123759A (no) |
| CN (1) | CN1890260A (no) |
| AR (1) | AR047263A1 (no) |
| AT (1) | ATE444305T1 (no) |
| AU (1) | AU2004294376A1 (no) |
| BR (1) | BRPI0417309A (no) |
| CA (1) | CA2547317A1 (no) |
| CU (1) | CU23237A1 (no) |
| DE (1) | DE602004023419D1 (no) |
| ES (1) | ES2334138T3 (no) |
| NO (1) | NO20063020L (no) |
| NZ (1) | NZ547520A (no) |
| PL (1) | PL1693378T3 (no) |
| RU (1) | RU2336900C2 (no) |
| WO (1) | WO2005054281A2 (no) |
| ZA (1) | ZA200604556B (no) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117483A (en) * | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
| CU22559A1 (es) | 1996-01-17 | 1999-05-03 | Ct Ingenieria Genetica Biotech | Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión |
| EP2261338A3 (en) * | 1998-05-01 | 2012-01-04 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
| ES2323845T3 (es) | 1999-04-30 | 2009-07-27 | Novartis Vaccines And Diagnostics, Inc. | Secuencias genomicas de neisseria y procedimientos de uso. |
| GB9911683D0 (en) * | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
| GB9911692D0 (en) * | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic combinations |
-
2003
- 2003-12-03 CU CU20030285A patent/CU23237A1/es unknown
-
2004
- 2004-12-01 AR ARP040104481A patent/AR047263A1/es unknown
- 2004-12-02 ES ES04802607T patent/ES2334138T3/es not_active Expired - Lifetime
- 2004-12-02 BR BRPI0417309-0A patent/BRPI0417309A/pt not_active IP Right Cessation
- 2004-12-02 AU AU2004294376A patent/AU2004294376A1/en not_active Abandoned
- 2004-12-02 RU RU2006123434/13A patent/RU2336900C2/ru not_active IP Right Cessation
- 2004-12-02 DE DE602004023419T patent/DE602004023419D1/de not_active Expired - Lifetime
- 2004-12-02 AT AT04802607T patent/ATE444305T1/de not_active IP Right Cessation
- 2004-12-02 CA CA002547317A patent/CA2547317A1/en not_active Abandoned
- 2004-12-02 US US10/580,508 patent/US7691971B2/en not_active Expired - Fee Related
- 2004-12-02 NZ NZ547520A patent/NZ547520A/xx unknown
- 2004-12-02 EP EP04802607A patent/EP1693378B9/en not_active Expired - Lifetime
- 2004-12-02 WO PCT/CU2004/000015 patent/WO2005054281A2/es not_active Ceased
- 2004-12-02 CN CNA2004800358779A patent/CN1890260A/zh active Pending
- 2004-12-02 PL PL04802607T patent/PL1693378T3/pl unknown
- 2004-12-02 KR KR1020067010712A patent/KR20060123759A/ko not_active Ceased
-
2006
- 2006-06-02 ZA ZA200604556A patent/ZA200604556B/xx unknown
- 2006-06-28 NO NO20063020A patent/NO20063020L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2547317A1 (en) | 2005-06-16 |
| EP1693378A2 (en) | 2006-08-23 |
| US7691971B2 (en) | 2010-04-06 |
| ZA200604556B (en) | 2007-03-28 |
| WO2005054281A3 (es) | 2005-08-04 |
| AR047263A1 (es) | 2006-01-11 |
| US20070218000A1 (en) | 2007-09-20 |
| DE602004023419D1 (de) | 2009-11-12 |
| RU2006123434A (ru) | 2008-01-10 |
| BRPI0417309A (pt) | 2007-09-11 |
| CU23237A1 (es) | 2007-09-26 |
| AU2004294376A1 (en) | 2005-06-16 |
| PL1693378T3 (pl) | 2010-03-31 |
| WO2005054281A2 (es) | 2005-06-16 |
| KR20060123759A (ko) | 2006-12-04 |
| ATE444305T1 (de) | 2009-10-15 |
| EP1693378B9 (en) | 2010-05-19 |
| NZ547520A (en) | 2009-07-31 |
| CN1890260A (zh) | 2007-01-03 |
| RU2336900C2 (ru) | 2008-10-27 |
| EP1693378B1 (en) | 2009-09-30 |
| ES2334138T3 (es) | 2010-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007054279A3 (en) | Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions | |
| MX2022010175A (es) | Proteinas de union a flt3 y metodos de uso. | |
| WO2007149715A3 (en) | Novel dna sequences, vectors and proteins of avian influenza hemagglutinin | |
| WO2008033375A3 (en) | Long lasting drug formulations | |
| WO2007022425A3 (en) | Influenza recombinant subunit vaccine | |
| NO20111324A1 (no) | Rekombinant MVA-virus | |
| EP2163260A3 (en) | Chimpanzee adenovirus vaccine carriers | |
| MX2010012999A (es) | Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso. | |
| TNSN07087A1 (en) | Stable liquid formulations of plasmid dna | |
| WO2009009759A3 (en) | Yersinia pestis antigens, vaccine compositions, and related methods | |
| DK2010563T3 (da) | Syntetisk MeCP2 sekvens til proteinsubstitutionsterapi | |
| BR0309570A (pt) | Fatores camp quiméricos para vacinação contra infecção por streptococcus | |
| ATE473283T1 (de) | Dna-expressionsvektoren | |
| NO20063017L (no) | Protein NMB0928 og anvendelse derav i farmasoytiske formuleringer | |
| NO20060813L (no) | Syntetisk gen som koder for human epidermalvekstfaktor 2/NEU og andvendelser derav | |
| WO2007059931A8 (en) | New adjuvants on the basis of bisacyloxypropylcysteine conjugates and derivatives and their uses in pharmaceutical compositions | |
| Wang et al. | Two oral HBx vaccines delivered by live attenuated Salmonella: both eliciting effective anti-tumor immunity | |
| NO20063020L (no) | Protein NMB1125 og anvendelse derav i farmasoytiske formuleringer | |
| DE602004024968D1 (de) | Francisella-stamm für lebenden impfstoff | |
| WO2019033007A3 (en) | Staphylococcus pseudintermedius virulence factor compositions | |
| NO20084525L (no) | Farmasoytiske sammensetninger inneholdende NMB0606-protein | |
| Silveira et al. | Saccharomyces boulardii improves humoral immune response to DNA vaccines against leptospirosis | |
| NO20084524L (no) | Farmasoytisk sammensetning inneholdende NMB0938-protein | |
| ES2401276B1 (es) | Utilización de una construcción genica y/o peptídica para la fabricación de una vacuna para la prevención y/o tratamiento de la infección causada por el virus de la peste porcina africana (vppa). | |
| NO20083318L (no) | Farmasoytiske sammensetninger inneholdende protein NMA0939 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |